Social Determinants of Health Are Associated With Treatment Receipt and Mortality in Patients With Hepatocellular Carcinoma.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: hepatocellular carcinoma (HCC) remains unclear
I · Intervention 중재 / 시술
HCC treatment, of whom 46
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
추출되지 않음
[BACKGROUND] The association between social determinants of health (SDOH) and clinical outcomes among patients with hepatocellular carcinoma (HCC) remains unclear.
- 표본수 (n) 475
- 95% CI 0.28-0.98
- 연구 설계 cohort study
APA
Al-Hasan M, Rich NE, et al. (2026). Social Determinants of Health Are Associated With Treatment Receipt and Mortality in Patients With Hepatocellular Carcinoma.. Journal of the National Comprehensive Cancer Network : JNCCN, 24(2), 19-26. https://doi.org/10.6004/jnccn.2025.7095
MLA
Al-Hasan M, et al.. "Social Determinants of Health Are Associated With Treatment Receipt and Mortality in Patients With Hepatocellular Carcinoma.." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 24, no. 2, 2026, pp. 19-26.
PMID
41698343 ↗
Abstract 한글 요약
[BACKGROUND] The association between social determinants of health (SDOH) and clinical outcomes among patients with hepatocellular carcinoma (HCC) remains unclear.
[METHODS] We conducted a retrospective cohort study of patients with treatment-naïve HCC seen between September 2018 and July 2023 at 4 US health systems. Patients completed surveys assessing SDOH and health beliefs. We used multivariable logistic regression analysis to identify factors associated with treatment receipt and Fine-Gray subdistribution hazard analysis to identify factors associated with risk of death, with liver transplantation as a competing event.
[RESULTS] Among 770 eligible patients (55.1% with Barcelona Clinic Liver Cancer [BCLC] stage 0/A HCC), 73.2% received HCC treatment, of whom 46.8% received curative therapy. Treatment receipt was inversely associated with alcohol-associated liver disease (ALD) etiology (adjusted odds ratio [aOR], 0.52; 95% CI, 0.28-0.98), Child-Pugh class B (aOR, 0.45; 95% CI, 0.27-0.75), medical mistrust (aOR, 0.61; 95% CI, 0.38-0.98), and patient-reported discrimination (aOR, 0.80; 95% CI, 0.76-0.83). After adjusting for tumor stage and type of HCC treatment, Child-Pugh class B cirrhosis was associated with a higher risk of mortality (subdistribution hazard ratio [sHR], 1.41; 95% CI, 1.05-1.89), whereas patient-reported discrimination was associated with a lower risk of mortality (sHR, 0.96; 95% CI, 0.94-0.99). Among follow-up survey respondents (n=475), those who reported barriers to treatment had lower treatment receipt (aOR, 0.79; 95% CI, 0.65-0.93), whereas those who reported better patient-provider communication had lower mortality (sHR, 0.95; 95% CI, 0.92-0.99).
[CONCLUSIONS] Patient-reported medical mistrust, experienced discrimination, and barriers to treatment are associated with treatment receipt and survival, underscoring the importance of addressing SDOH and health beliefs to improve outcomes in patients with HCC.
[METHODS] We conducted a retrospective cohort study of patients with treatment-naïve HCC seen between September 2018 and July 2023 at 4 US health systems. Patients completed surveys assessing SDOH and health beliefs. We used multivariable logistic regression analysis to identify factors associated with treatment receipt and Fine-Gray subdistribution hazard analysis to identify factors associated with risk of death, with liver transplantation as a competing event.
[RESULTS] Among 770 eligible patients (55.1% with Barcelona Clinic Liver Cancer [BCLC] stage 0/A HCC), 73.2% received HCC treatment, of whom 46.8% received curative therapy. Treatment receipt was inversely associated with alcohol-associated liver disease (ALD) etiology (adjusted odds ratio [aOR], 0.52; 95% CI, 0.28-0.98), Child-Pugh class B (aOR, 0.45; 95% CI, 0.27-0.75), medical mistrust (aOR, 0.61; 95% CI, 0.38-0.98), and patient-reported discrimination (aOR, 0.80; 95% CI, 0.76-0.83). After adjusting for tumor stage and type of HCC treatment, Child-Pugh class B cirrhosis was associated with a higher risk of mortality (subdistribution hazard ratio [sHR], 1.41; 95% CI, 1.05-1.89), whereas patient-reported discrimination was associated with a lower risk of mortality (sHR, 0.96; 95% CI, 0.94-0.99). Among follow-up survey respondents (n=475), those who reported barriers to treatment had lower treatment receipt (aOR, 0.79; 95% CI, 0.65-0.93), whereas those who reported better patient-provider communication had lower mortality (sHR, 0.95; 95% CI, 0.92-0.99).
[CONCLUSIONS] Patient-reported medical mistrust, experienced discrimination, and barriers to treatment are associated with treatment receipt and survival, underscoring the importance of addressing SDOH and health beliefs to improve outcomes in patients with HCC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.